ANVS - Annovis And Alzheimer's Disease: The Best-Laid Plans

2024-01-29 23:44:21 ET

Summary

• Annovis will likely announce results from it Parkinson's disease and Alzheimer's disease trials in the next couple of month.
• Annovis inhibits the formation of the amyloid precursor protein.
• The primary triggers for Alzheimer's disease are unrelated to amyloid, making it unlikely that Annovis' buntanetap will substantially impact disease progression.
• Anti-amyloid drugs only slow down the progression of Alzheimer's disease in its early stages in APOE4 carriers and may not be effective in the long-term.

Finding an effective treatment for Alzheimer’s disease reminds me of the classical game labyrinth: no matter how long and how hard one tries, the ball always falls through a hole rather than making it to the end....

For further details see: